Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance.

Armed with a fresh $40 million series B round, Anokion S.A. is developing a platform to treat autoimmune disease by inducing tolerance via liver-targeted autoantigens (see “Anokion’s autoimmunity platform evolution”)...